IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Rhinomed is a Public Company that generates the majority of its income from the Medical & Surgical Equipment Manufacturing industry. In 2025 the company generated total revenue of $10,031,000 including sales and other revenue. The exact number of employees for this organisation is not available. The Chief Executive of Rhinomed is Mr Michael Johnson whose official title is Managing Director & Chief Executive Officer. The Chairman of Rhinomed is Mr Ron Dewhurst whose official title is Non-Executive Chairman. Rhinomed Limited is an airway technology company that seeks to improve the way you breathe, sleep, maintain your health and take medication. The company’s primary revenue comes from the manufacture of products for: Breathing - Snoring is a sign a sign that we are not breathing well at night. By delivering more air through the nose, Rhinomed’s Mute technology may reduce the incidence and severity of snoring. Sleep - Pronto is a next generation vapour inhaler with a dual action. Pronto both opens the nose to improve airflow and delivers soothing vapors from our special essential oil blends. The company has developed two products in this area – Pronto Sleep and Pronto Clear. Pronto Sleep is designed to help you relax, fall asleep and stay asleep naturally. Pronto Clear is designed to clear a stuffy nose naturally, for fast and lasting relief, day or night. Sport - Rhinomed Limited has developed the product Turbine, aimed at providing athletes with easier breath whilst participating on the track, on the field, on the bike or during a workout. COVID- 19 - In response to the COVID-19 pandemic, Rhinomed applied its nasal airway technology to help address the global swab supply shortage. This resulted in the development of the Rhinoswab to test for COVID-19. It was proven to be 100% accurate for the detection of SARS-COV-2 in spiking studies conducted by the Victorian Infectious Diseases Laboratory.
Answer any industry question in minutes with our entire database at your fingertips.
Feed trusted, human-driven industry intelligence straight into your platform.
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
IBISWorld's research coverage on the Rhinomed Limited includes market sizing, forecasting, data and analysis. The most recent publication will be as current as of March 2026.
Rhinomed Limited, trading as , operates under the ABN and was incorporated on . Rhinomed Limited trades on the Australian Securities Exchange under the ticker code ASX:. Rhinomed Limited primarily operates in the Medical & Surgical Equipment Manufacturing industry in Australia.
The Key Personnel chapter outlines the principal leadership positions within Rhinomed Limited, including the Chairman, Board members, Chief Executive Officer, and other key management personnel. It provides an overview of the company’s governance and executive structure, along with a breakdown of gender diversity across leadership roles, offering insight into the composition of the organisation’s senior team.
The Financials chapter presents Rhinomed Limited’s historical financial performance, including detailed profit and loss statements outlining sales revenue, cost of sales, and profitability. It also incorporates balance sheet data, providing a breakdown of assets and liabilities, as well as additional financial metrics such as the number of shares on issue. Together, these disclosures offer a comprehensive view of the company’s financial position and performance over time.
The Growth & Ratios chapter provides historical data on key financial performance indicators, enabling an assessment of the company’s operational efficiency, profitability, and financial structure over time. Metrics covered include return on equity, return on assets, profit margins, revenue per employee, as well as gearing and leverage ratios, offering a comprehensive view of performance trends and capital management.
The Operating Segments chapter provides an overview of the revenue composition and asset allocation across the various industries in which Rhinomed Limited operates. It offers insights into how the company’s financial performance is distributed among its core business segments, highlighting the relative contribution of each industry to total revenue.
The Competitor Benchmarking chapter includes a comparative assessment of Rhinomed Limited’s key financial, growth, and valuation ratios against industry averages to evaluate its competitive position. It analyses valuation metrics such as price-to-earnings, price-to-book, enterprise value to EBITDA, and enterprise value to sales, alongside core financial indicators including liquidity ratios and profitability measures.
The Shareholders chapter provides a breakdown of the ownership structure of Rhinomed Limited, identifying key shareholders and outlining their respective ownership interests. This section offers insight into the concentration of shareholdings, the presence of institutional or strategic investors, and the overall distribution of equity within the company.
The Subsidiaries chapter provides an overview of the companies and business entities that are wholly or partially owned by Rhinomed Limited. It outlines the ownership structure of each subsidiary, offering insight into the broader corporate group and how these entities contribute to the company’s overall activities and performance.
The History chapter presents a overview of Rhinomed Limited’s development, highlighting key milestones and significant corporate events since its incorporation. It includes the company’s incorporation date and outlines major strategic, operational, and structural developments, providing context for its evolution and current market position.
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.